Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04353336 |
Recruitment Status :
Completed
First Posted : April 20, 2020
Last Update Posted : August 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 Coronavirus Infection | Drug: Chloroquine or Hydroxychloroquine | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 194 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment |
Actual Study Start Date : | March 23, 2020 |
Actual Primary Completion Date : | June 1, 2020 |
Actual Study Completion Date : | July 1, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Chloroquine or Hydroxychloroquine
Chloroquine or Hydroxychloroquine with standard of care treatment.
|
Drug: Chloroquine or Hydroxychloroquine
Chloroquine or Hydroxychloroquine
Other Name: alexoquine, chloroquine, Hydroquine |
No Intervention: No intervention
standard of care treatment alone.
|
- Number of patients with cure or death [ Time Frame: 1 month ]the number of patients with cure or death

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Covid 19 patients
Exclusion Criteria:
- Allergy or contraindication to the drug
- Pregnant or lactating
- Patients with cardiac problems

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04353336
Egypt | |
Tanta University, Assiut University | |
Tanta, Egypt, 35111 |
Principal Investigator: | sherief Abd-Elsalam, Ass. Prof. | Tanta University - Faculty of Medicine |
Responsible Party: | Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University |
ClinicalTrials.gov Identifier: | NCT04353336 |
Other Study ID Numbers: |
chloroquine covid |
First Posted: | April 20, 2020 Key Record Dates |
Last Update Posted: | August 2, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Coronavirus Infections Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Hydroxychloroquine Chloroquine Chloroquine diphosphate |
Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antirheumatic Agents Amebicides Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents |